WeVote
Log In

Bill

Bill

H 4952

An Act relative to the diagnosis and treatment of autism spectrum disorder

194th Legislature (2025-2026) Introduced by Patrick Kearney and 1 co-sponsor

The bill aims to improve access to timely autism diagnosis and cover a broader range of ASD therapies through required insurance and public program coverage.

Reporting date extended to Thursday, December 31, 2026
0
WeVote Research Nonpartisan
Bill Summary · H 4952

Overview

H.4952, an Act relative to the diagnosis and treatment of autism spectrum disorder, is a Massachusetts bill introduced in the 194th Session. The bill aims to improve access to diagnosis and treatment for individuals with autism spectrum disorder (ASD) and to establish standards and coverage related to ASD services within the Commonwealth. The latest action history indicates a reporting date extension to December 31, 2026, with prior committee actions in 2026 related to Financial Services and Health Care Financing.

Purpose and intent

  • To enhance diagnostic processes and treatment options for ASD.
  • To expand or clarify coverage and access to ASD-related services for individuals and families.
  • To align state practices with recognized diagnostic and therapeutic standards for ASD, potentially affecting insurers, providers, and public programs.

Key provisions and changes (as indicated by the bill’s scope and related committee actions)

Note: The exact statutory text is not provided here, but based on the bill’s title and typical provisions for ASD-related legislation, expected areas include:
- Diagnostic access: Measures to support timely and accurate ASD diagnosis for children and potentially adults, including screening requirements or guidelines for clinicians.
- Treatment coverage: Provisions that may require insurance plans (private and/or state-funded programs) to cover ASD-related therapies (e.g., behavioral therapy such as applied behavior analysis, speech and occupational therapy) and axial services, with defined standards for duration and frequency.
- Service delivery standards: Establishment of evidence-based practice requirements, qualified providers, and possibly regional service coordination mechanisms.
- Public program alignment: Potential integration with MassHealth or state-funded services to ensure eligibility and access to ASD-related care.
- Cost containment or rate setting: Provisions that address reimbursement rates, pilot programs, or oversight to monitor expenditures related to ASD services.
- Consumer protections: Safeguards for patients and families, including dispute resolution or appeal processes for coverage determinations.

Who would be affected

  • Individuals diagnosed with autism spectrum disorder and their families, who could benefit from enhanced diagnosis timelines and broader coverage of therapeutic services.
  • Health insurers and managed care organizations operating in Massachusetts, which may be required or encouraged to cover specified ASD services and treatments.
  • Healthcare providers (pediatricians, psychiatrists, therapists, and behavior analysts) delivering ASD diagnostic and therapeutic services, with potential changes in practice standards and documentation requirements.
  • State agencies and public programs (e.g., MassHealth/Medicaid), which would implement and oversee any mandated coverage, guidelines, or funding mechanisms.
  • Employers and groups offering private insurance plans to Massachusetts residents, depending on the bill’s scope regarding coverage mandates.

Procedural and timeline aspects

  • The bill was reported favorably by the committee and referred to the Committee on Health Care Financing (as of January 28, 2026).
  • The Financial Services Committee also engaged with the bill, indicating potential provisions affecting financial regulation, insurance markets, or consumer protections related to ASD services.
  • Reporting date extended: The current action history shows an extension of the reporting date to Thursday, December 31, 2026, implying a continuation of consideration and potential amendments through late 2026.
  • Sponsors: Co-sponsors John Mahoney and Patrick Kearney, indicating bipartisan consideration.

Potential impact and considerations

  • Improvements in early detection and timely access to ASD therapies could lead to better long-term outcomes for individuals with ASD.
  • Financial implications for insurers and public programs, including potential new coverage requirements and rate considerations.
  • Implementation would require clear definitions of covered services, provider qualifications, and cost-control measures to ensure sustainability.
  • Monitoring and evaluation provisions (if included) would help assess effectiveness, access, and expenditures related to ASD services.

If you’d like, I can tailor this summary to focus on specific sections (e.g., exact coverage mandates, eligibility criteria, or funding provisions) once the full text is available.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.